



Contact: CEOcast, Inc.
Dan Schustack
Investor Relations
212-732-4300
DSchustack@ceocast.com

ImmunoCellular Therapeutics to Present Clinical Data from ICT-107 at Leading Neurology Conference

LOS ANGELES, CA – May 4, 2010 – ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced that John S. Yu, M.D., the company’s Chief Scientific Officer and Chairman of the Board, will present clinical data from ICT-107, the company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM), at the 78th American Association of Neurological Surgeons (AANS) Annual Meeting at the Pennsylvania Convention Center in Philadelphia. Dr. Yu’s presentation, titled “Targeting Cancer Stem Cells”, is scheduled for today at 3:30 p.m. During the presentation, Dr. Yu will also present pre-clinical data from ICT-121, ImmunoCellular Therapeutics’ “off the shelf” therapeutic vaccine product candidate targeting cancer stem cells (CSC’s) for multiple cancer indications.

The Company plans to initiate a Phase II trial for ICT-107 by the end of this year.

Dr. Yu was one of the first to isolate CSCs from brain tumors. In a recent Phase I study of ICT-107 in GBM, newly diagnosed patients who received the vaccine demonstrated a median progression-free survival (PFS) of 17.7 months after surgery. This compared favorably with the historical median PFS of 6.9 months observed with standard treatment with surgery, radiation and chemotherapy. Seven of the 16 patients (44%) who participated in the study continue to live with no disease progression with an average time over 2 years, which is significantly better than historical data of less than 15% disease free survival. The Company expects to initiate a Phase I clinical trial for ICT-121 for glioblastoma during the second half of 2010.

The American Association of Neurological Surgeons (AANS) Conference brings together leading neurologists and neurosurgeons from its membership of over 7,600 worldwide. The AANS is dedicated to advancing the specialty of neurological surgery in order to provide the highest quality of neurosurgical care to the public. All Active members of the AANS are board certified by the American Board of Neurological Surgery, the Royal College of Physicians and Surgeons of Canada, or the Mexican Council of Neurological Surgery. The event takes place from May 1st to May 5th.

About ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter phase II study in the

second half of 2010. The Company's "off the shelf" therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the second half of 2010. IMUC has entered into a research and license option deal with the Roche Group for one of the Company's monoclonal antibody product candidates for the diagnosis and treatment of ovarian cancer and multiple myeloma, which provides for potential licensing and milestone payments of \$32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery to target cancer stem cells. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation, the risks associated with the potential inability to obtain licenses from third parties that will be needed to commercialize ICT-107 in many major commercial territories; the potential inability to secure a partner to fund development and marketing of ICT-107; the risk that future trials of ICT-107, if any, do not confirm the safety and efficacy data generated in the Phase I trial; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with obtaining a patent that provides commercially significant protection for ICT-107; the risk of encountering substantial delays in completing or being unable to successfully complete the pre-clinical testing necessary before initiating clinical testing of ICT-121; and the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages and to continue IMUC's operations. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###